Cornerstone Research (London)

Sinan Corus

Cornerstone Research (London)

Sinan Corus is a manager at Cornerstone Research based in the firm’s London office. He provides economic and financial analysis and expert support in all phases of commercial litigation in the U.K., U.S., and Europe. His experience includes merger review; assessment of economic damages related to disputes involving monopolization, product liability, alleged corporate disclosure misrepresentations, and unfair pricing; and ex post assessment of competition policy actions. Sinan Corus has managed teams conducting sophisticated empirical analyses with large, complex datasets.

Linked authors

Cornerstone Research (London)
Cornerstone Research (San Francisco)
Cornerstone Research (Chicago)
Cornerstone Research (San Francisco)
Cornerstone Research (Washington)


1099 Bulletin

Margaret Kyle, Vivek Mani, Sinan Corus Intellectual property & Competition law: An overview of EU and national case law


In this article, we consider some recent high-profile cases in the EU and the US where intellectual property (IP) rights and competition policy intersect, and discuss the impact of IP rights on the competitive assessment. We begin with reverse payment agreements, and consider the Court of Justice of the European Union (CJEU) judgements in Paroxetine and Lundbeck. Next, we discuss the US Court of Appeals for the Ninth Circuit judgement in FTC v. Qualcomm and the court’s insights on how to assess the competitive effects of licensing practices. We then consider the European Commission’s (the “Commission’s”) recent Aspen investigation and excessive pricing assessments. Finally, we turn to merger control, and describe the role of IP rights in vertical mergers. We conclude by noting rising concerns about transactions that may have an adverse effect on future competition.

1085 Review

Margaret Kyle, Sinan Corus, Julia Tanndal The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation


One goal of the European Commission’s proposed reform to existing regulations is to increase patient access to innovative medicines across the European Union. We describe the economic impact of this policy change. Because of the incentives created by other policies, particularly external (...)


Total visits

Number of readings per contribution

Number of contributions

Author's ranking
In number of contributions
In number of visits
In average number of visits
Send a message